| Theme | Serve Acute Pancreatitis -- Prediction of Deterioration and Therapeutic Strategy | |
|---|---|---|
| Title | Indications and Efficacy of Blood Purification for Severe Acute Pancreatitis | |
| Publish Date | 2001/07 | |
| Author | Shigeto Oda | Department of Emergency and Critical Care Medicine, Chiba University School of Medicine |
| Author | Hiroyuki Hirasawa | Department of Emergency and Critical Care Medicine, Chiba University School of Medicine |
| Author | Nobuya Kitamura | Department of Emergency and Critical Care Medicine, Chiba University School of Medicine |
| Author | Ken-ichi Matsuda | Department of Emergency and Critical Care Medicine, Chiba University School of Medicine |
| [ Summary ] | Recently, it has come to be widely accepted that acute pancreatitis (AP) is one of the typical clinical conditions associated with systemic inflammatory response syndrome (SIRS) caused by hypercyto kinemia, which is induced by local inflammation of the pancreas, and that deterioration and prolongation of SIRS causes organ dysfunction and severe acute pancreatitis (SAP). It has also been elucidated that continuous hemodiafiltration (CHDF) with a PMMA hemofilter can effectively remove various humoral mediators, such as cytokines, from the blood stream and that these clinical benefits have been gradually recognized. CHDF, which was originally developed as a form of continuous renal replacement therapy, is now applied to the treatment of SAP, in order to remove causative humoral mediators with non-renal indications. Early application of CHDF would be beneficial for the prevention of organ dysfunction in SAP and would improve mortality rates in patients with SAP. | |